Researchers have revealed that it is now possible to determine the rate of body aging based on a single brain image, ...

Global healthcare specialist Open Healthcare has established the Korean Medical Center (KMC) in Almaty, Kazakhstan. Open ...

Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued; ...

Alector Therapeutics is shelving a GSK-partnered antibody after the asset failed to slow disease progression in patients with ...

A study in the Journal of Orthopaedic Research uses a noninvasive, nonradioactive imaging-based method to measure the ...

This represents Alector's second failed neurodegenerative asset in a year, after an AbbVie-partnered asset missed in ...

The initiative is part of the company's efforts to expand the use of brain MRI technology across various healthcare settings.

A study in the Journal of Orthopaedic Research uses a noninvasive, nonradioactive imaging-based method to measure the ...

Magnetic resonance imaging (MRI) holds great potential to spare men with suspected prostate cancer a painful biopsy. In our ...

Non-invasive device worn on the forehead uses laser technology and an array of detectors, and could form the basis of methods for monitoring brain blood flow.

Biotechnology company Alector announced today that the drug, latozinemab, failed to meet the criteria for safety and efficacy in a Phase 3 clinical trial. The study investigated the drug as an ...